We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




First-Ever Implantable Device Detects Organ Transplant Rejection Three Weeks Earlier Than Current Methods

By HospiMedica International staff writers
Posted on 20 Oct 2023

Organ rejection is a concern that can happen at any stage after a kidney transplant, and it often occurs without clear symptoms. More...

People with a transplanted kidney have to keep a constant eye on its health. Currently, the simplest way to do this is by measuring levels of markers like creatinine and blood urea nitrogen in the blood. However, these markers can fluctuate for reasons that aren't related to organ rejection, making them unreliable indicators that can result in false positives or negatives. Additional blood markers can help but are not perfectly reliable either. The current gold standard for identifying organ rejection is a biopsy, but it's an invasive procedure with its own set of risks. Now, a first-ever device to monitor transplanted organs can sense warning signs of rejection up to three weeks earlier than current methods.

Researchers at Northwestern University (Evanston, IL, USA) have created the first electronic device designed to continuously monitor the health of a transplanted organ in real time. This soft, ultrathin implant sits directly on the transplanted kidney and monitors temperature fluctuations, which are often related to inflammation and other bodily reactions that can indicate transplant rejection. Since inflammation is usually accompanied by a rise in temperature, the researchers reasoned that unusual temperature increases could act as early indicators of potential rejection issues. The device then sends this data wirelessly to a nearby smartphone or tablet, alerting the patient or medical professionals.

In a new study, the team tested this implant on a small animal model with transplanted kidneys. They found that the device could pick up early signs of organ rejection up to three weeks before traditional monitoring methods could. Specifically, they observed that the temperature of a transplanted kidney could rise by up to 0.6 degrees Celsius before any signs of rejection appeared. In animals not taking immunosuppressive drugs, this temperature increase occurred a few days before any changes in blood biomarkers were noticeable. For animals on immunosuppressive medication, not only did the temperature rise, but it also showed other irregularities, even three weeks before creatinine and blood urea nitrogen levels changed. The new device, therefore, not only identifies the early signs of rejection but also provides continuous, real-time monitoring.

“We imagine that a surgeon could implant the device immediately following the transplant surgery, while the patient is still in the operating room,” said Northwestern’s John A. Rogers, a bioelectronics pioneer who led the device development. “Then, it can monitor the kidney without requiring additional procedures.”

“All electronic components are encased in a soft, biocompatible plastic that is gentle and flexible against the kidney’s delicate tissues,” said Surabhi Madhvapathy, a graduate student in Rogers’ laboratory. “The surgical insertion of the entire system, which is smaller than a quarter, is a quick and easy procedure.”

Related Links:
Northwestern University 


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Gas Analyzer
GE SAM
Gold Member
Blood Gas Analyzer
i-Check200
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Artificial intelligence (AI) standalone performance and reader performance with versus without AI assistance. (A) Receiver operating characteristics (ROC) curve for AI standalone performance in the US dataset (AUC 0.899, 95% CI 0.858 to 0.939). (B) ROC curve for AI standalone performance in the Korean dataset (AUC 0.963, 95% CI 0.946 to 0.975). (C) Pooled reader ROC without (AUC 0.718) versus with (AUC 0.852) AI assistance in the Korean dataset; P<0.001. AUC, area under the receiver operating characteristics curve. (Leonard Sunwoo et al., Journal of NeuroInterventional Surgery (2026). DOI: 10.1136/jnis-2026-025339)

AI Improves Non-Contrast CT Interpretation for Time-Sensitive Stroke Assessment

Acute ischemic stroke occurs when a blood vessel in the brain becomes blocked, requiring rapid diagnosis to enable timely reperfusion therapy. Emergency departments often use computed tomography angiography... Read more

Surgical Techniques

view channel
Image: The thin foetoscope is guided through the abdominal wall to the placenta. Small magnets in its tip react to an externally generated magnetic field, enabling the instrument to be bent with precision. The robotic platform is designed to occlude shared blood vessels in the placenta of twins with twin-to-twin transfusion syndrome. (Image Credit: created with BioRender.com, ETH Zurich)

Robotic Platform Advances Fetoscopic Treatment of Twin-to-Twin Transfusion Syndrome

Twin-to-twin transfusion syndrome is a life-threatening complication in monochorionic twin pregnancies caused by unbalanced placental blood flow. Definitive treatment requires endoscopic laser coagulation... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.